Statin Drugs

The statin drugs, also known as HMG-CoA reductase inhibitors, are the most popular and powerful medications for lowering cholesterol. They work by interfering with HMG-CoA reductase, an enzyme necessary for the body's manufacture of cholesterol. Drugs in this family include:

Chaparral, Comfrey, and Coltsfoot
Possible Harmful Interaction

The herb chaparral (Larrea tridentate or L. mexicana ) has been promoted for use in arthritis, Cancer, and various other conditions, but there is insufficient evidence supporting its effectiveness. There are, however, concerns about its apparent liver toxicity.

Several cases of chaparral-induced liver damage have been reported, some of them severe enough to require liver transplantation. 1-6
Based on these reports, combining chaparral with other agents that are hard on the liver, such as statin drugs, may amplify the risk of potential liver problems. 7 Other herbs that are toxic to the liver include comfrey (Symphytum officinale) and coltsfoot (Tussilago farfara).

St. John's Wort
Possible Harmful Interaction

The herb St. John’s wort, used to treat depression, may decrease blood levels of various drugs in the statin family, including simvastatin, lovastatin, and atorvastatin (but not pravastatin). 22

Grapefruit Juice
Possible Harmful Interaction

Grapefruit juice impairs the body's normal breakdown of several drugs, including statins, allowing them to build up to potentially excessive levels in the blood. 8 A recent study indicates that this effect can last for 3 days or more following the last glass of juice. 9

Because this could increase the risk of serious drug side effects, if you take interacting statins, the safest approach is to avoid grapefruit juice altogether. Grapefruit juice may not affect fluvastatin or pravastatin because these drugs are broken down differently than other statins.10

Vitamin B3
Possible Benefits and Risks

Niacin (nicotinic acid) is vitamin B3. In high doses (often 1500 mg daily or more), niacin is effective in lowering cholesterol levels. Its other form, niacinamide (nicotinamide), does not affect cholesterol.

Combining high-dose niacin with statin drugs further improves cholesterol profile by raising HDL (“good") cholesterol. 23, 24, 25 Unfortunately, there are real concerns that this combination therapy could cause a potentially fatal condition of muscle breakdown called rhabdomyolysis.

A growing body of evidence, however, suggests that the risk is relatively slight in individuals with healthy kidneys. Furthermore, even much lower doses of niacin than the usual dose given to improve cholesterol levels (100 mg versus 1000 mg or more) may provide a similar benefit. 26 At this dose, the risk of rhabdomyolysis should be decreased. Nonetheless, it is not safe to try this combination except under close physician supervision. Rhabdomyolysis can be fatal.

Pomegranate
Possible Harmful Interaction

One case report suggests that consumption of pomegranate juice might increase the risk of rhabdomyolosis with rosuvastatin (Crestor). 28

Red Yeast Rice
Possible Harmful Interaction

Red yeast rice is an herbal cholesterol-lowering therapy. It contains a mixture of statins; its primary statin ingredient is lovastatin, making it most closely resemble the prescription drug Mevacor.

Based on the similarity of red yeast rice to statin drugs, the two should not be combined without medical supervision.

CoEnzyme Q-10 (CoQ-10)
Supplementation Probably Helpful

CoEnzyme Q-10 (CoQ-10 ) is a vitamin-like substance that plays a fundamental role in the body's energy production 13,14 and appears to be important for normal heart function. 15

Statin drugs inhibit the enzyme necessary for the body's synthesis of both cholesterol and CoQ-10. Several studies (including two double-blind trials) have found that these drugs reduce CoQ-10 levels in the body. 16,17,18 Because statin drugs are used to protect the heart by lowering cholesterol levels, their effect of inhibiting CoQ-10 production might be counterproductive.

Taking CoQ-10 supplements prevents the lowering of CoQ-10 levels caused by statin drugs, and does so without interfering with their therapeutic effects. 20

One study found that statin-induced lowering of tissue CoQ-10 levels may worsen heart function in people with Cardiomyopathy, a disease of the heart muscle. 19 Individuals most vulnerable to this effect appear to be those with low CoQ-10 levels and impaired heart function to begin with. When the study participants were given oral CoQ-10 supplementation (100 to 200 mg/day), their CoQ-10 blood levels increased and their deteriorating heart function improved.

Another study in a broader population failed to find any correlation between levels of CoQ-10 and rate of adverse events. 27 This was an observational study, however, and therefore not very reliable.

Fish Oil
Supplementation Probably Helpful

Fish oil is thought to help protect against heart disease. A 1-year double-blind, placebo-controlled trial found that use of fish oil enhanced the benefits of simvastatin, further reducing triglyceride levels. 21 In another study, use of DHA (a component of fish oil) significantly enhanced the effectiveness of statin therapy. 29 A daily dose of eight grams daily was more effective than four grams daily.

REFERENCES:
  1. Alderman S, Kailas S, Goldfarb S, et al. Cholestatic hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy. J Clin Gastroenterol. 1994;19:242-247.
  2. [No authors listed]. From the Centers for Disease Control and Prevention. Chaparral-induced toxic hepatitis-California and Texas, 1992. JAMA. 1992;268:3295, 3298.
  3. Gordon DW, Rosenthal G, Hart J, et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA. 1995;273:489-490.
  4. Katz M, Saibil F. Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf. J Clin Gastroenterol. 1990;12:203-206.
  5. Smith BC, Desmond PV. Acute hepatitis induced by ingestion of the herbal medication chaparral [letter]. Aust N Z J Med. 1993;23:526.
  6. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med. 1997;157:913-919.
  7. Jim LK, Gee JP. Adverse effects of drugs on the liver. In: Young LY, Koda-Kimble MA (eds). Applied Therapeutics: The Clinical Use of Drugs. Vancouver, Wash: Applied Therapeutics, Inc.; 1995:26.1-26.17.
  8. A to Z Drug Facts [book on CD-ROM]. 2nd ed. St. Louis, Mo: Facts and Comparisons; 2000.
  9. Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther. 2000;67:201-214.
  10. A to Z Drug Facts [book on CD-ROM]. 2nd ed. St. Louis, Mo: Facts and Comparisons; 2000.
  11. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73:25D-29D.
  12. Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated [abstract]. J Am Coll Cardiol. 2000;35(2 suppl A):A326.
  13. Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q-10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137-S144.
  14. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ-10 -lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-229.
  15. Mortensen SA, Vadhanavikit S, Muratsu K, et al. CoEnzyme Q-10 : clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12:155-162.
  16. Mortensen SA, Leth A, Agner E, et al. Dose-related decrease of serum coenzyme Q-10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137-S144.
  17. Ghirlanda G, Oradei A, Manto A, et al. Evidence of plasma CoQ-10 -lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993;33:226-229.
  18. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA. 1990;87:8931-8934.
  19. Folkers K, Langsjoen P, Willis R, et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA. 1990;87:8931-8934.
  20. Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ-10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res. 1994;24:171-176.
  21. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001;85:544-548.
  22. Sugimoto Ki K, Ohmori M, Tsuruoka S, et al. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther . 2001;70:518-524.
  23. Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73:25D-29D.
  24. Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J Am Coll Cardiol. 2000;35(suppl A):326.
  25. Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 2001;87:476-479.
  26. Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J. 2002;143:514-518.
    Stocker R, Pollicino C, Gay CA et al. Neither plasma coenzyme Q(10) concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: A prospective case-control study from the LIPID study. Atherosclerosis . 2005; Oct 8 [Epub ahead of print].
  27. Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol . 2006;98:705-6.
  28. Meyer BJ, Hammervold T, Rustan AC, et al. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids . 2007;42:109-15.
  29. Marcoff L, Thompson PD. The role of coenzyme Q-10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49:2231-2237.

Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTH CARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health care provider prior to starting any new treatment or with any questions you may have regarding a medical condition.

Edits to original content made by TriVita.

Copyright © 2009 EBSCO Publishing All rights reserved.